Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$25.15 USD
+0.49 (1.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 41 - 49 ( 49 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early Phase 2 Results Make Polycythemia Vera the Focus for PTG-300
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Some Patience Is Needed, But Three Assets Moving Towards Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PD Data Robust; But We Still Await Clinical Proof of Concept
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let''s Not Jump to Conclusions on PTG-300; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PN-943 Continues to Look Promising; Reiterating Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D